One step forward, one step sideways? Expanding research capacity for neglected diseases

BMC International Health and Human Rights

Volumn 10, Issue 1, 2010, Pages

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CHAGAS DISEASE; DEVELOPING COUNTRY; DIABETES CONTROL; DRUG INDUSTRY; FUNDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIASIS; LICENSING; NEOPLASM; PUBLIC-PRIVATE PARTNERSHIP; RESEARCH; REVIEW; STRENGTH; TECHNOLOGY;

EID: 77954462385     PISSN: None     EISSN: 1472698X     Source Type: Journal    
DOI: 10.1186/1472-698X-10-20     Document Type: Review

References (51)

1. S Finkelstein P Temin, Reasonable Rx: solving the drug price crisis Upper Saddle River: FT Press 2008
2. Novartis chief in warning on cheap drugs. A Jack, Financial Times 2006 8
3. Global framework on essential health R&D. P Chirac E Torreele, Lancet 2006 367 1560 1561 10.1016/S0140-6736(06)68672-8 16698397
4. Fatal imbalance: the crisis in research and development for drugs for neglected diseases. Drugs for Neglected Diseases Working Group, Campaign for Access to Essential Medicines, Geneva: Médecins Sans Frontières Access to Essential Medicines Campaign and Drugs for Neglected Diseases Working Group 2001
5. The new landscape of neglected disease drug development. M Moran AL Ropars J Guzman J Diaz C Garrision, London: Wellcome Trust 2005
6. Macroeconomics and health: investing in health for economic development. Commission on Macroeconomics and Health, Geneva: World Health Organization 2001
7. Public health innovation and intellectual property rights. Commission on Intellectual Property Rights Innovation and Public Health, Geneva: World Health Organization 2006
8. The world health report: 2003 - shaping the future. World Health Organization, Geneva: World Health Organization 2003
9. MA Burke SA Matlin (Eds), Monitoring financial flows for health research 2008 Geneva: Global Forum for Health Research 2008
10. WHO's budgetary allocations and burden of disease: a comparative analysis. D Stuckler L King H Robinson M McKee, Lancet 2008 372 1563 1569 10.1016/S0140-6736(08)61656-6 18984189
11. Donor funding priorities for communicable disease control in the developing world. J Shiffman, Health Policy and Planning 2006 21 411 420 10.1093/heapol/czl028 16984894
12. WHO official complains about Gates Foundation's dominance in malaria fight. DG McNeil Jr, New York Times 2008
13. Gates's grandest challenge: transcending technology as public health ideology. AE Birn, Lancet 2005 366 514 519 10.1016/S0140-6736(05)66479-3 16084261
14. Public-private partnerships and scientific imperialism. TJ Tucker WM Makgoba, Science 2008 320 1016 1017 10.1126/science.1156720 18497279
15. Seven habits of highly effective global public-private health partnerships: practice and potential. K Buse AM Harmer, Social Science & Medicine 2007 64 259 271
16. Ending the R&D crisis in public health: promoting pro-poor medical innovation. R Malpani C Heineke M Kamal-Yanni, Oxford: Oxfam International 2008
17. 'Making the money work'*: challenges towards coordination of HIV/AIDS programmes in Africa. SB Helleviik, Health for some: the political economy of global health governance Hampshire: Palgrave Macmillan, Maclean SJ, Brown SA, Fourie P, 2009 145 161
18. A social explanation for the rise and fall of global health issues. J Shiffman, Bulletin of the World Health Organization 2009 87 608 613 10.2471/BLT.08.060749 19705011
19. The benefits of medical research and the role of the NIH. United States Senate 2000
20. Academic patents and access to medicines in developing countries. BN Sampat, American Journal of Public Health 2009 99 9 17 10.2105/AJPH.2007.128769 19008514
21. University licensing. JG Thursby MC Thursby, Oxford Review of Economic Policy 2007 23 620 639 10.1093/oxrep/grm031
22. Improving access to medicines in poor countries: the role of universities. DA Chokshi, PLoS Medicine 2006 3 6 136 10.1371/journal.pmed. 0030136 16608382
23. Can patents deter innovation? The anticommons in biomedical research. MA Heller RS Eisenberg, Science 1998 280 698 701 10.1126/science.280.5364.698 9563938
24. Innovation in biomedicine: can stem cell research lead the way to affordability. M Goozner, PLoS Medicine 2006 3 5 126 10.1371/journal.pmed. 0030126 16492088
25. Patent pools: an idea whose time has come. E Sukkar, BMJ 2009 338 974 10.1136/bmj.b1630
26. Drug giant GlaxoSmithKline pledges cheap medicine for world's poor. S Boseley, Guardian 2009
27. GlaxoSmithKline urged to pool its patents on HIV drugs. S Boseley, Guardiain 2009
28. UNITAID: together to heal, 2009. http://www.unitaid.eu/
29. A patent pool for medicines: more medicines. E 't Hoen T von Schoen-Angerer, The World Today. Volume 68 Chatham House 2009 30 31
30. Clinical trials offshored: on private sector science and public health. A Petryna, BioSocieties 2007 2 21 40 10.1017/S1745855207005030
31. Effective drug regulation: what can countries do? Geneva: World Health Organization 1999 http://whqlibdoc.who.int/hq/1999/WHO-HTP-EDM-MAC(11)-99.6.pdf
32. Ethical review of health research: a perspective from developing country researchers. AA Hyder SA Wali AN Khan NB Teoh NE Kass L Dawson, Journal of Medical Ethics 2004 30 68 72 10.1136/jme.2002.001933 14872079
33. How does the regulatory framework affect incentives for research and development. P Matsoso M Auton S Banoo, Geneva: CIPIH Study Paper 2005
34. Three proposals for rewarding novel health tehcnologies benefiting people living in poverty: a comparative analysis of prize funds, health impact funds and a cost-effectiveness/competitive tender treaty. TA Faunce, Public Health Ethics 2008 1 146 153 10.1093/phe/phn013 19461854
35. A Hollis T Pogge, The health impact fund: making new medicines accessible for all Incentives for Global Health 2008
36. Measures to enhance access to medical technologies, and new methods of stimulating medical R&D. J Love, UC Davis Law Review 2007 40 679 715
37. Scrooge and intellectual property rights. JE Stiglitz, BMJ 2006 333 1279 1280 10.1136/bmj.39048.428380.80 17185703
38. The big idea: prizes to stimulate R&D for new medicines. J Love T Hubbard, Chicago-Kent Law Review 2007 82 1519 1544
39. The health impact fund: pay-for-performance. T Pogge A Hollis P Singer C Nathan A Banerjee, et al. http://www.yale.edu/macmillan/igh/files/ IGHsubmissionV6.pdf
40. Pharmaceutical company funding and its consequences: a qualitative systematic review. S Sismondo, Contemporary Clinical Trials 2008 29 109 113 10.1016/j.cct.2007.08.001 17919992
41. Medicines agencies do not demand sufficient comparative evaluation. Prescrire International 2003 12 113 114
42. Using economic evaluations to make formulary coverage decisions: so much for guidelines. AH Anis Y Gagnon, Pharmacoeconomics 2000 18 55 62 10.2165/00019053-200018010-00006 11010604
43. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. SR Hill AS Mitchell DA Henry, JAMA 2000 283 2116 2221 10.1001/jama.283.16.2116 10791503
44. Review of company postmarketing surveillance studies. PC Waller SM Wood MJS Langman AM Breckenridge MD Rawlins, BMJ 1992 304 1470 1472 10.1136/bmj.304.6840.1470 1611368
45. Bringing the FDA's information to market. S Woloshin LM Schwartz, Archives of Internal Medicine 2009 169 1985 1987 10.1001/archinternmed.2009.399 19933960
46. Drug development for neglected diseases - the trouble with FDA review vouchers. AS Kesselheim, New England Journal of Medicine 2008 359 1981 1983 10.1056/NEJMp0806684 18987367
47. The U.S. FDA priority review voucher. The right mechanism to develop drugs for neglected diseases. or corporate welfare in disguise? L Pope, Geneva: Médecins sans Frontières, Campaign for Access to Essential Medicines 2008
48. KEI comments to the priority review voucher mechanism. Washington: Knowledge Ecology International 2008
49. Drug companies as organizational hybrids. W Kaplan, The power of pills: social, ethical & legal issues in drug development, marketing & pricing London: Pluto Press, Cohen JC, illingworth P, Schüklenk, 2006 41 56
50. Investing for life: meeting poor people's needs for access to medicines through responsible business practices. HV Fiestas, Oxfam Briefing Paper Oxfam International 2007
51. Public-private partnerships for product development: financial, scientific and managerial issues as challenges for the future. E Ziemba, Geneva: CIPIH Research Report 2005